571
Views
7
CrossRef citations to date
0
Altmetric
Review

An update on first line therapies for metastatic breast cancer

, , &
Pages 243-252 | Received 14 Mar 2017, Accepted 05 Jan 2018, Published online: 16 Jan 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Palma Fedele, Valeria Sanna, Alessandro Fancellu & Saverio Cinieri. (2019) A clinical evaluation of treatments that target cell cycle machinery in breast cancer. Expert Opinion on Pharmacotherapy 20:18, pages 2305-2315.
Read now
Carlos Martínez-Pérez, Arran K Turnbull & J Michael Dixon. (2019) The evolving role of receptors as predictive biomarkers for metastatic breast cancer. Expert Review of Anticancer Therapy 19:2, pages 121-138.
Read now
Hongli Gao, Guijun Hao, Yue Sun, Liye Li & Yukun Wang. (2018) Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process. OncoTargets and Therapy 11, pages 8001-8012.
Read now

Articles from other publishers (4)

Kellsye P. Fabian, Joshua T. Kowalczyk, Sandy T. Reynolds & James W. Hodge. (2022) Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. Cells 11:23, pages 3826.
Crossref
Jiayi Huang, Xue Bai, Xiaofeng Xie, Liping Chen, Xiaofeng Lan, Qiuyi Zhang, Lin Song, Pengjiao Hong & Caiwen Du. (2022) A Real-World Study on Oral Vinorelbine for the Treatment of Metastatic Breast Cancer. Oncologie 24:1, pages 131-145.
Crossref
Ye Han, Xiaopeng Yu, Shuqiang Li, Ye Tian & Caigang Liu. (2020) New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. Frontiers in Oncology 10.
Crossref
I. Blancas, E. Aguirre, S. Morales, M. L. Gonzálvez, S. Servitja, N. Díaz, S. del Barco, A. Barnadas, M. Margelí, I. García Carbonero & A. Llombart. (2018) Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens. Clinical and Translational Oncology 21:4, pages 459-466.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.